Xinogen will make upfront and milestone payments and also pay royalties on sales, though specific details were not disclosed.
Xinogen (Hong Kong) Pharma will collaborate with Montreal’s Angiochem to develop AngioChem‘s paclitaxel-Angiopep-2 conjugate in China. ANG1005 is aimed at treating leptomeningeal carcinomatosis, a neurological metastasis, from breast cancer. Xinogen is a subsidiary of Beijing Shenogen Pharma, a company that is developing small molecule and biologic treatments for cancer. Xinogen, which acquired China rights to develop and commercialize ANG1005, will make upfront and milestone payments and also pay royalties on sales, though specific details were not disclosed.
